Compare Amgen, Inc. (AMGN) vs Plby Group Inc (PLBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Plby Group Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Plby Group Inc trades at $1.16 (market cap $134.09M). The key difference: Amgen, Inc. is far larger — about 1462.6× Plby Group Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.
| AMGN | PLBY | |
|---|---|---|
Market Cap | $196.12B | $134.09M |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $2.71 |
52-Week Low | $271.18 | $1.14 |
Enterprise Value | $241.41B | $281.90M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
PLBY trades at $1.16 with no recent price movement, showing technical bearish signals despite oversold RSI readings. The company has shown improving fundamentals with revenue stabilizing around $120-122 million and narrowing losses from -$278M in 2022 to -$13M in 2025. Recent positive developments include Russell index inclusion and a strategic share repurchase program. Operating cash flow turned positive in 2025 after years of negative performance, though the company maintains high debt levels with a debt-to-asset ratio of 59.52%.
While PLBY shows operational improvement and strong analyst support (75% buy ratings), significant risks remain including negative shareholder equity, high debt burden, and inconsistent earnings performance. The stock presents a turnaround opportunity if management can sustain EBITDA growth and debt reduction, but requires careful monitoring of cash flow sustainability and licensing revenue stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
